Special Issue "Targeting the Eph–ephrin System"
Deadline for manuscript submissions: closed (31 March 2020).
Interests: Pharmacology; intestinal inflammation; Eph-ephrin system; Eph-ephrin ligands; cholinergic receptors; mesenteric ischemia-reperfusion; serotonin and histamine ligands.
The interest in the Eph–ephrin system has significantly and progressively grown during the last 25 years, as testified by the exponential rise in the number of scientific articles dealing with Eph receptors and their ephrin ligands from 1994 onwards. Eph receptor tyrosine kinases and their ephrin counterparts, comprising A- and B-type ephrins, uniquely stand out for their contact-dependent bidirectional signalling in neighbouring Eph- and ephrin-bearing cells. Largely involved in cellular proliferation and adhesion/repulsion responses, the Eph–ephrin system has a foremost role during embryonic life in regulating morphogenesis and organogenesis. Moreover, as it is now increasingly emerging, it is crucial in tissue regeneration/remodelling and in cancer progression and angiogenesis in post-natal life. Intriguingly, in the adult, this signalling pathway is also involved in several other pathophysiological conditions, such as inflammation and atherosclerosis, neurological disorders, diabetes, and bone diseases.
Proposed strategies to pharmacologically modulate Eph–ephrin signalling pathways include agonists, such as anti-Eph monoclonal antibodies and dimeric Fc-conjugated Eph–ephrin proteins, and antagonists, such as kinase inhibitors and protein–protein interaction inhibitors, some of which are already being tested in clinical studies. However, several problems, including the promiscuity of Eph–ephrin interactions, the complexity of Eph–ephrin intracellular signalling, and the sometimes disparate cellular outcomes that are triggered, have hindered up to now the full clinical exploitation of the available candidate drugs.
The present Special Issue of Pharmaceuticals is focused on “Targeting the Eph–ephrin system” and it aims to be an up-to-date collection of manuscripts and review articles dealing with the manifold challenges posed by this signalling pathway. The proposed topics will comprise the role of Eph–ephrin forward and reverse signaling, kinase-dependent and -independent signaling, Eph–ephrin system in cancer and non-cancer pathologies, and therapeutic strategies to target and modulate Eph–ephrin pathways. This Special Issue will mirror the state of the art in this field of investigation and will help to highlight original lines of research.
I warmly hope that you will be able to submit your valuable contribution as an original article or review dealing with research in this area of investigation.
Prof. Bertoni Simona
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.